

Mechanistic definition of the cardiovascular mPGES-1/COX-2/ADMA axis

Nicholas S. Kirkby ^{1*†}, Joan Raouf^{2†}, Blerina Ahmetaj-Shala^{1†}, Bin Liu ³, Sarah I. Mazi^{1,4}, Matthew L. Edin⁵, Mark Geoffrey Chambers⁶, Marina Korotkova ², Xiaomeng Wang^{7,8,9,10}, Walter Wahli ^{7,11}, Darryl C. Zeldin⁵, Rolf Nüsing¹², Yingbi Zhou³, Per-Johan Jakobsson^{2,13‡}, and Jane A. Mitchell^{1*‡}

¹National Heart & Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK; ²Unit of Rheumatology, Department of Medicine, Karolinska Institute, Stockholm, Sweden; ³Cardiovascular Research Centre, Shantou University Medical College, Shantou, China; ⁴King Fahad Cardiac Center, King Saud University, Riyadh, Saudi Arabia; ⁵National Institute for Environmental Health Sciences, Durham, NC, USA; ⁶Biotechnology and Autoimmunity Research, Eli Lilly and Company, Indianapolis, IN, USA; ⁷Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore, Singapore; ⁸Institute of Molecular and Cell Biology, Agency for Science Technology & Research, Singapore, Singapore; ⁹Department of Cell Biology, Institute of Ophthalmology, University College London, London, UK; ¹⁰Singapore Eye Research Institute, Singapore, Singapore; ¹¹Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland; ¹²Clinical Pharmacology and Pharmacotherapy Department, Goethe University, Frankfurt, Germany; and ¹³Karolinska University Hospital, Stockholm, Sweden

Received 9 October 2018; revised 23 May 2019; editorial decision 26 October 2019; accepted 31 October 2019; online publish-ahead-of-print 5 November 2019

Time for primary review: 41 days

Aims

Cardiovascular side effects caused by non-steroidal anti-inflammatory drugs (NSAIDs), which all inhibit cyclooxygenase (COX)-2, have prevented development of new drugs that target prostaglandins to treat inflammation and cancer. Microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors have efficacy in the NSAID arena but their cardiovascular safety is not known. Our previous work identified asymmetric dimethylarginine (ADMA), an inhibitor of endothelial nitric oxide synthase, as a potential biomarker of cardiovascular toxicity associated with blockade of COX-2. Here, we have used pharmacological tools and genetically modified mice to delineate mPGES-1 and COX-2 in the regulation of ADMA.

Methods and results

Inhibition of COX-2 but not mPGES-1 deletion resulted in increased plasma ADMA levels. mPGES-1 deletion but not COX-2 inhibition resulted in increased plasma prostacyclin levels. These differences were explained by distinct compartmentalization of COX-2 and mPGES-1 in the kidney. Data from prostanoid synthase/receptor knockout mice showed that the COX-2/ADMA axis is controlled by prostacyclin receptors (IP and PPAR β/δ) and the inhibitory PGE₂ receptor EP4, but not other PGE₂ receptors.

Conclusion

These data demonstrate that inhibition of mPGES-1 spares the renal COX-2/ADMA pathway and define mechanistically how COX-2 regulates ADMA.

* Corresponding authors. Tel: +442075947922, E-mail: n.kirkby@imperial.ac.uk (N.S.K.); Tel: +442075947922, E-mail: j.a.mitchell@ic.ac.uk (J.A.M.)


† The first three authors contributed equally to this study.

‡ The last two authors contributed equally to this study.

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Graphical Abstract



Keywords

Vioxx • Non-steroidal anti-inflammatory drugs • Methylarginines • ADMA • COX-2 • Prostacyclin • PGE2

1. Introduction

Cyclooxygenase (COX) is a ubiquitous checkpoint in cardiovascular homeostasis and is present in two forms, COX-1 and COX-2.¹ COX-1 is constitutively expressed throughout the body, including in platelets² and endothelial cells,³⁻⁵ whilst COX-2 is restricted to specific regions⁶ which include the kidney⁶⁻⁹ where it is present in numerous cell types including fibroblasts, tubular epithelial cells, and endothelial cells.⁹ COX-1 in platelets drives prothrombotic thromboxane^{4,10} and is the therapeutic target of low-dose aspirin.¹¹ In contrast, constitutively expressed COX-2 protects the cardiovascular system. We know this because mice lacking COX-2 are prone to atherosclerosis,¹²⁻¹⁶ thrombosis,¹⁷⁻¹⁹ and hypertension^{8,19} and because the non-steroidal anti-inflammatory drugs (NSAIDs) class of drugs, which all work by blocking COX-2-derived prostaglandin (PG)E₂ and other prostanoids at the site of inflammation,

cause much reported cardiovascular side effects. These side effects are associated with all members of the NSAID class except aspirin and increase personal risk of having a heart attack or stroke by as much as 30%²⁰⁻²³ even after only 2 weeks of regular use.²³ Importantly, they amount to a global problem because NSAIDs are amongst the most commonly used pain medications worldwide and can prevent cancer. However, the precise mechanism(s) by which NSAIDs cause cardiovascular side effects are not completely understood causing serious consequences including that (i) there are no means of identifying patients at risk, (ii) NSAIDs are not used to prevent cancer, and (iii) the development of new drugs that target prostanoids has declined.

What we do know is that inhibition of protective prostanoids, particularly prostacyclin or PGE₂, derived from constitutively expressed COX-2 in the kidney⁸ or at other sites,^{19,24} underpins cardiovascular toxicity of NSAIDs. With this in mind, selective drug targeting of PGE₂

at the site of inflammation may well provide a therapeutic strategy to treat disease whilst sparing the release of cardioprotective prostanooids. This could be achieved by inhibition of microsomal prostaglandin (PG) E synthase-1 (mPGES-1), a prostaglandin synthase, which converts intermediates produced by COX-1 and COX-2 to proinflammatory PGE₂.²⁵ Inhibition of mPGES-1 is a well-developed area of pre-clinical research with studies showing that its genetic deletion protects against inflammation, pain and cancer,^{26–28} however, clinical development of mPGES-1 as a therapeutic target has been stopped. In some cases, this has been for specific reasons such as liver toxicity associated with LY3023703,²⁹ but overall reflects a lack of a complete understanding surrounding NSAID cardiovascular toxicity and of relevant biomarkers.

Most recently work from our group⁸ and others¹⁹ has shown a link between inhibition of COX-2 and the endothelial nitric oxide synthase (eNOS) pathway which helps to explain how COX-2 protects the cardiovascular system. Our work additionally implicates the naturally occurring eNOS inhibitors asymmetric dimethylarginine (ADMA)⁸ and/or monomethylarginine (LNMA)⁸ as biomarkers and mechanistic explanations of how loss of COX-2 mediates vascular dysfunction. ADMA is an established cardiovascular biomarker in both preclinical and clinical studies.³⁰ However, the precise role of prostacyclin synthase (PGIS), mPGES-1, and associated downstream receptor signalling in the COX-2/ADMA axis is not known.

Thus, in the current study, we have used pharmacological tools and a full range of genetically modified mice to determine the precise involvement of COX-2, mPGES-1, PGIS, and respective prostanoid signalling receptors in the regulation of ADMA. This work validates and explains the 'COX-2-ADMA axis' and suggests an empirical estimation of the relative cardiovascular safety of mPGES-1 and COX-2 as therapeutic targets in man.

2. Methods

2.1 Animals

Male and female, 6- to 8-week-old wild-type mice, or mice lacking mPGES-1,³¹ PGIS (newly generated, see below), IP,³² PPAR β/δ ,³³ EP1,³⁴ EP2,³⁵ EP3,³⁶ EP4,³⁷ or DP1³⁸ were used. Animals were housed in individually ventilated cages, with 12 h day/night cycle and free access to standard mouse chow and water. Studies were performed across multiple institutes, however in each case, (i) wherever possible samples were collected and data analysed by investigators blinded to the genotype/treatment of the animals, (ii) the same investigators collected and analysed tissue in all studies, (iii) tissue from relevant control animals was collected at the same time from the same source, and (iv) experiments were performed in accordance with all local guidelines, legislation and after ethical review and the Animals (Scientific Procedures) Act (1986) Amendment (2013). Experiments on mPGES-1^{-/-} mice, PGIS^{-/-} mice, and PPAR β/δ ^{-/-} mice were performed at the Karolinska Institute, Sweden (approved by Karolinska Institute ethics committee, dnr. N86_13 and N364_11), Shantou Medical University, China (approved by the Shantou University Institutional Animal Research and Use Committee), and Nanyang Technological University, Singapore (approved by the Nanyang Technological University and SingHealth Institutional Animal Care and Use Committees in Singapore; IACUC SHS-868), respectively. For each of these lines corresponding wild-type littermates from the same colony were used as controls. Experiments on IP^{-/-}, DP1^{-/-}, EP1^{-/-}, EP2^{-/-},

EP3^{-/-}, and EP4^{-/-} mice were performed at Goethe University, Germany (approved by the Animal Welfare Committee of the State Agency Darmstadt). These animals were maintained on a pure C57Bl/6 background and compared to age- and sex-matched C57Bl/6 mice from a separate colony held at the same institute. Experiments on IP^{-/-} and DP1^{-/-} were performed on separate occasions to those on EP1-4^{-/-} mice and therefore have their own individual control groups. All other experiments were performed at Imperial College London, UK (approved by the Imperial College Animal Welfare and Ethical Review Board under UK Home Office license 70/8422) on wild-type C57Bl/6 animals (Charles River, UK). Where indicated, wild-type mice were treated with the selective COX-2 inhibitor, parecoxib (100 mg/kg; Pfizer, USA) in drinking water for 5 days.⁸

2.2 Generation of PGIS^{-/-} mice

PGIS^{-/-} mice were generated by Beijing View Solid Biotechnology (Beijing, China) using transcription activator-like effector nuclease (TALEN).³⁹ TALEN constructs targeting exon 2 of the *Ptgis* locus were designed by using TAL Effector Nucleotide Targeter 2.0 (<https://tale-nt.cac.cornell.edu/node/add/talen>). The target sequences were: left 5'-GAGCCTCCGTTGGACCT-3' and right 5'-CCAAGGCATGGCCCAGC-3'. All constructs were validated by DNA sequencing. TALEN mRNA was injected into mouse (C57Bl/6) zygotes which were then transferred to pseudopregnant females to generate mutant founders (F₀). Founders carrying frameshift mutations were intercrossed with wild-type mice to produce the F₁ generation. PCR was performed with tail clip DNA from weaned mice with the primers: 5'-CAGCCTA CTCTGACTTCCCCATG-3' and 5'-GGGTGAGTGAAAGCGTATT TAATC-3' for sense and antisense primers respectively. Mice were genotyped by sequencing the PCR products. The T7E1 (Beijing View Solid Biotechnology) assay was used to validate targeting efficiency and screen for the desired mutant mice. F₁ mice with deletion of 14 bp (GCAGCATCCCCTGG) in exon 2 of the *Ptgis* locus were bred to produce PGIS^{-/-} mice.

2.3 Circulating mediators

Mice were killed by CO₂ narcosis, blood collected from the inferior vena cava into heparin (10 U/mL final; Leo Laboratories, UK) and plasma separated. Levels of ADMA and arginine (DLD Diagnostika, Germany), the prostacyclin break-down product, 6-keto-PGF_{1 α} (Cayman Chemical, USA), or creatinine (Cayman Chemical, USA) were measured by commercial biochemical/immunoassay kit.

2.4 Prostanoid release and measurement

Prostanoid release *ex vivo* was measured as we have previously described.^{4,6} Briefly, segments of renal medulla, renal cortex or aorta were incubated in DMEM media (Sigma, UK) containing Ca²⁺ ionophore A23187 (30 μ mol/L; Sigma, UK) for 30 min at 37°C then release of PGE₂ or 6-keto-PGF_{1 α} was measured by immunoassay (Cisbio, France and Cayman Chemical, USA, respectively). In some cases, levels of a panel of eicosanoids was measured in the supernatant using an LC/MS/MS platform as previously described.⁴⁰

2.5 Gene and protein expression

RNA was isolated from renal medulla and gene expression determined using TaqMan hydrolysis probes (Life Technologies, UK). Data were normalized to expression of the housekeeping genes 18S (probe ID: Mm03928990_g1) and *Gapdh* (probe ID: Mm99999915_g1) and relative




Figure 1 Effects of COX-2 inhibition and mPGES-1 gene deletion on plasma ADMA and 6-ketoPGF_{1α} in mice. Plasma levels of ADMA (A) or 6-ketoPGF_{1α} (B) in wild-type mice treated for 5 days with parecoxib (100 mg/kg/day p.o.) or mPGES-1 gene knockout (KO) mice. Data are mean ± S.E.M. (A–B): * $P < 0.05$ by one-way ANOVA with Dunnett's *post hoc* test from $n = 7$ mice per group.

expression compared using the comparative Ct method. Protein was isolated by homogenizing frozen tissue in PBS containing a protease inhibitor cocktail (Roche Bioscience, UK). mPGES-1 protein levels were measured using a specific ELISA (Mybiosource, USA) and normalized to total protein levels determined using the bicinchoninic acid method (Thermo Fisher Scientific, UK).

2.6 Statistics and data analysis

Data were analysed using Prism 7.0 software (Graphpad software, USA) and are presented as mean ± standard error for 'n' number of animals. *N* values for individual studies are given in figure legends. The experimental design for the primary endpoint of the study (plasma ADMA levels in mice where mPGES-1 was deleted or COX-2 was inhibited; Figure 1A) was based on formal power calculations. Effect size and variance were estimated from our previously published data on plasma ADMA in mice treated with parecoxib⁸ (Cohen's $D = 1.67$) such that $n = 7$ provided 81% power by detect a significant difference ($P < 0.05$; two-tailed) in a three-group comparison. Subsequent mechanistic experiments were not the subject of formal power calculations. Differences were considered significant if $P < 0.05$. Details of statistical tests applied are given in each figure legend.

3. Results and discussion

3.1 Differential effects of mPGES-1 and COX-2 inhibition on plasma ADMA and prostacyclin

Two biomarkers have emerged as candidates to assess and predict the cardiovascular toxicity of anti-inflammatory drugs targeting COX-2 and/or the prostaglandin cascade. The first of these is prostacyclin, which is well established as a cardinal cardiovascular protective mediator derived from the COX pathway. Metabolites of prostacyclin can be measured in the urine, but these can be produced in the kidney⁴¹ and do not necessarily reflect prostacyclin production in the circulation.^{4,42,43} Instead, the prostacyclin breakdown product 6-keto-PGF_{1α} can be measured in the plasma, levels of which do correlate with prostacyclin production by systemic blood vessels.^{4,6,44} The second is ADMA, an established predictor of cardiovascular risk in the general population.^{30,45} Although to date no

clinical data are available for the association between ADMA levels and cardiovascular risk in NSAID users, plasma ADMA is increased in COX-2 knockout mice with no associated change in plasma prostacyclin.⁸ Here, we show that ADMA is similarly increased plasma of wild-type mice where COX-2 is inhibited pharmacologically with chronic dosing (5 days) of parecoxib (Figure 1A). As with genetic deletion,⁸ COX-2 inhibition with parecoxib did not affect plasma levels of prostacyclin (Figure 1B). In contrast, loss of mPGES-1 had no effect on plasma ADMA but increased plasma prostacyclin (Figure 1A and B). We have previously shown that the increase in ADMA seen in COX-2 knockout mice is associated with renal dysfunction and mediated by changes in methylarginine-processing enzymes in the kidney.⁸ This point was recently corroborated in studies showing that ADMA was not increased and methylarginine genes not altered in models of reduced COX-2 that spare the kidney.⁴⁶ In the current study plasma creatinine, a standard marker for predicting renal impairment, was increased in mice treated with parecoxib (Figure 2A) but unaffected in mPGES-1 knockout mice (Figure 2A). In line with this parecoxib increased expression of the gene encoding the ADMA synthetic enzyme PRMT1 (*Prmt1*; Figure 2B) and reduced expression of the gene encoding the ADMA metabolizing enzyme AGXT2 (*Agxt2*; Figure 2C). In contrast, deletion of mPGES-1 had no effect on *Prmt1* or *Agxt2* expression (Figure 2), which explains the lack of change in circulating ADMA levels (Figure 1E). Neither parecoxib treatment nor mPGES-1 deletion influenced expression of the gene encoding the alternative ADMA metabolic enzyme DDAH1 (*Ddah1*; Figure 2D). These observations suggest that, in direct contrast to COX-2 inhibition, targeting mPGES-1 spares both general renal function and the protective effects of renal COX-2 on the ADMA pathway. These findings agree with reports that mPGES-1 has a minimal role in the regulation of blood pressure and salt/water handling by the kidney in animal models⁴⁷ and that in human healthy volunteers small, sporadic changes in plasma creatinine levels are not associated with changes in glomerular filtration rate or blood pressure.⁴⁸ This further corroborates the idea that unlike COX-2, mPGES-1 does not play a substantial role in controlling cardiovascular physiology.⁴⁹

With the data above demonstrating that mPGES-1 inhibition spares the renal COX-2/methylarginine pathway and boosts circulating prostacyclin levels, we went on to use these models to perform mechanistic investigations. We addressed the two underlying questions: (i) how and why do mPGES-1 inhibitors spare the COX-2/ADMA axis and (ii) how




Figure 2 COX-2 but not mPGES-1 controls renal function and expression of methylarginine-related genes in the renal medulla. Plasma creatinine levels in wild-type mice treated for 5 days with parecoxib (100 mg/kg/day p.o.) or in mice where mPGES-1 has been knocked out (KO) (A). mRNA expression by qPCR of *Prmt1* (B), *Agxt2* (C), and *Ddah1* (D) in renal medulla of wild-type mice, wild-type mice treated with parecoxib or and mPGES-1 KO mice. Data are mean \pm S.E.M. * $P < 0.05$ by one-way ANOVA with Dunnett's *post hoc* test from $n = 7$ –12 mice per group.

does mPGES-1 blockade boost vascular prostacyclin production? These are considered in turn below.

3.2 How does mPGES-1 blockade spare the COX-2/ADMA axis?

There are two possible scenarios that explain why loss of mPGES-1 does not result in increased ADMA. *Scenario 1:* PGE₂ signalling does not regulate ADMA. *Scenario 2:* PGE₂ does regulate ADMA but that mPGES-1 is not involved in PGE₂ formation at the site where methylarginines are processed. To address scenario 1, we used a range of genetically modified mice where individual prostanoid genes were deleted and measured plasma levels of ADMA.

The role of PGE₂ in the COX-2/ADMA axis has not been explored but there is evidence that implicates prostacyclin since we have previously reported that mice lacking the classical prostacyclin receptor, IP, have elevated plasma ADMA.⁸ However, in that study comparisons with other prostanoid pathways, including PGE₂, were not made.⁸ Since prostacyclin may signal through other non-IP, prostanoid receptors, as well as nuclear receptors of the PPAR family,⁵⁰ to fully evaluate the role of prostacyclin in controlling the renal ADMA axis, we generated a novel PGIS knockout mouse line where endogenous prostacyclin is completely removed and confirmed the predicted phenotype by measuring plasma 6-keto-PGF_{1 α} . Deletion of PGIS was associated with an almost complete loss of plasma prostacyclin (PGIS^{+/+}, 400.6 \pm 106.1 pg/mL; PGIS^{-/-}, 29.0 \pm 5.8 pg/mL; $P = 0.002$) and increased plasma ADMA (Figure 3A) to a similar degree as seen in mice treated with parecoxib (Figure 1E). To determine the signalling pathways downstream of prostacyclin generation responsible for ADMA regulation we studied mice lacking IP and

PPAR β/δ . Deletion of either IP (Figure 3B) or PPAR β/δ (Figure 3C) resulted in elevation of plasma ADMA levels. However, deletion of the prostaglandin D₂ receptor DP1, which can also be activated by prostacyclin and shares similar signalling to IP, had no effect on plasma ADMA levels (Figure 3D).

These data are entirely consistent with the idea that COX-2-derived prostacyclin production regulates ADMA levels but doesn't however, rule out a similar or complementary functional role for COX-2/mPGES-1-derived PGE₂. To address this possibility we studied ADMA levels in the plasma of a full range of PGE₂ receptor knockout mice. PGE₂ utilizes four classical receptors, EP1-4, each linked to distinct signalling cascades, with EP4 being associated with cardioprotective properties including vasodilation and inhibition of platelet aggregation.¹ Plasma ADMA was unaffected by deletion of EP1, EP2 or EP3 (Figure 3E). However, plasma ADMA was increased in EP4 knockout mice (Figure 3E). These observations suggest that both prostacyclin and PGE₂ exert breaks on plasma ADMA and thereby rule out scenario 1 as an explanation for why mPGES-1 blockade spares ADMA.

This leaves us with scenario 2; that mPGES-1 does not drive the 'protective' PGE₂ which limits ADMA levels *in vivo*. We know that constitutive COX-2 and methylarginine pathways are co-localized specifically within the renal medulla and that here, rather than the cortex, or another site, is where NSAIDs act to increase ADMA. We know that both mPGES-1 and COX-2 are constitutively expressed in the kidney and that deletion of either gene reduces urinary markers of PGE₂.^{18,51} Thus, to address scenario 2 we measured mPGES-1 expression and activity in the renal medulla and renal cortex. mPGES-1 was expressed at significantly higher levels in the renal cortex compared to the renal medulla at both the mRNA (Figure 4A) and protein level (Figure 4B) whilst, as we




Figure 3 Both prostacyclin and PGE₂ receptor signalling regulates plasma levels of ADMA. Plasma levels of ADMA in mice where prostacyclin synthase (A) or the prostacyclin receptors IP (B) or PPARβ/δ (C) or the PGE₂/PGD₂ receptors, DP1 (D) EP1, EP2, EP3, or EP4 (E) have been knocked out (KO). Data are mean ± S.E.M. for $n = 5$ – 15 mice in each group. Panel (B) includes $n = 7$ – 8 previously published values⁸ in addition to $n = 6$ – 7 new data points. * $P < 0.05$ by unpaired t-test (A–D) or one-way ANOVA with Dunnett's *post hoc* test (E).

have previously shown, COX-2 was expressed almost exclusively within the renal medulla (Figure 4C). In line with this PGE₂ levels in cortex from mPGES-1 knock out mice were reduced (Figure 4D) whilst levels in renal medulla were unchanged (Figure 4E). Levels of prostacyclin production by the renal cortex (wild type: 6.2 ± 0.7 ng/mL; mPGES-1^{-/-}: 5.8 ± 1.1 ; $P = 0.80$; $n = 5$) or renal medulla (wild type: 14.2 ± 2.8 ng/mL; mPGES-1^{-/-}: 19.2 ± 1.3 ; $P = 0.13$; $n = 5$) were not altered by deletion of mPGES-1 consistent with a specific effect on renal cortical PGE₂ production. These observations show that mPGES-1 and COX-2 are oppositely compartmentalized within the kidney and explain why, despite PGE₂ (via EP4) regulating ADMA, inhibiting mPGES-1 spares renal methylarginine processing. Although it would be advantageous to confirm this in human tissue such as biopsy material or cultured cells/organoids, such studies are limited by the rapid induction of COX-2 and mPGES-1 *ex vivo*.

3.3 How does mPGES-1 regulate prostacyclin production in vessels?

We next separately addressed the link between mPGES-1 deletion and vascular prostacyclin. The finding that deletion of mPGES-1 increases plasma prostacyclin is likely to reflect the well-recognized phenomenon that excess PGH₂ substrate can be diverted between prostanoid synthetic pathways. This is in agreement with previous reports that urinary prostacyclin metabolites are increased in healthy volunteers receiving the mPGES-1 inhibitor, LY3023703.⁴⁸ However, which tissues or

cellular sites are involved in the shunting of PGH₂ from mPGES-1 ⇒ PGIS are not known but important to consider since any drug which increases vascular prostacyclin has the potential to protect the cardiovascular system.

To understand the role that vascular PGIS plays in the shunting away from PGE₂ towards prostacyclin when mPGES-1 is blocked we studied isolated aorta from wild-type and knockout mice. In blood vessels, studied immediately post-mortem to exclude any possibility of artefactual enzyme induction,⁴ prostacyclin (6-ketoPGF_{1α}) was by far the most abundant prostanoid released, with levels ~10 times higher than PGE₂ (Figure 5). These observations are entirely consistent with what we know of vascular prostacyclin and PGE₂ production.^{1,4,13} Nevertheless, release of PGE₂ from freshly isolated aortic rings was reduced by mPGES-1 deletion (Figure 5A), suggesting mPGES-1 is constitutively expressed in large vessels where it contributes to physiological PGE₂ production. However, we did not detect any concomitant increase in prostacyclin associated with reduced PGE₂ production in the aorta (Figure 5B). Amongst other eicosanoids measured 12-HETE, 9-HODE, and 13-HODE dominated but were, as with prostacyclin, unaffected by mPGES-1 deletion (Figure 5C). These observations show that PGIS is expressed in excess in large blood vessels and that in this setting; the diversion of a small amount of PGH₂ substrate from mPGES-1 does not impact on total prostacyclin levels within the vasculature. Our vascular results are limited to studies of the mouse aorta, however, together these observations suggest that mPGES-1 ⇒ PGIS shunting occurs in




Figure 4 mPGES-1 and COX-2 have distinct compartmentalization within the kidney. Expression of mPGES-1 (*Ptges*) at mRNA level by qPCR (A) and protein level by ELISA (B) in renal cortex and medulla of wild-type mice. mRNA expression of COX-2 (*Ptgs2*) by qPCR in the renal cortex and renal medulla of wild-type mice (C). PGE₂ production by isolated segments of renal cortex (D) and medulla (E) from wild-type and mPGES-1 knockout (KO) mice. Data are mean \pm S.E.M. for $n = 5-8$ mice in each group. * $P < 0.05$ by unpaired *t*-test.




Figure 5 mPGES-1 contributes to constitutive vascular PGE₂ production but its deletion does not increase local production of prostacyclin or other eicosanoids. Release of PGE₂ (A) and 6-keto-PGF_{1 α} (stable breakdown product of prostacyclin) (B) and a full range of eicosanoids (C) by isolated aortic rings from wild-type and mPGES-1 knockout (KO) mice. For panel (C) only detectable eicosanoids are shown. The following mediators were assayed but were below limits of detection: PGH₂, 8-iso-PGF_{2 α} , 8-iso-PGE₂, 15-keto-PGE₂, 20-OH-PGF_{2 α} , LTC₄, LTD₄, 20-carboxy-LTB₄, 8-HETE, 19-HETE, 20-HETE, 20-HEPE, 11,12-EET, 8,9-EET, 17,18-DHET, 19,20-EpDPE, 12,13-EpOME, 12,13-DHOME, 9,10-DHOME, 9,10-DiHDP, 17,18-EpETE, 22-HD ω HE, AA, LA, 20-carboxy-AA. Data are mean \pm S.E.M. (A, B): * $P < 0.05$ by (A, B) unpaired *t*-test for $n = 5-7$ mice per group. (C) Unpaired *t*-test with Benjamini-Hochberg FDR correction for $n = 4$ mice per group.

localized vascular beds or extra-vascular sites, the location of which remains the subject of investigation. Similarly, the potential for increased prostacyclin at those locations within the body to protect the cardiovascular (or other) systems has yet to be determined.

4. Conclusion

Our data show that in mouse models blocking mPGES-1 spares the COX-2/ADMA axis whilst increasing plasma prostacyclin levels. Further, mechanistic studies using mouse models suggest this can be explained by distinct compartmentalization of COX-2 and mPGES-1 in the kidney and the role of specific prostacyclin-sensitive receptors (IP, PPAR β/δ and EP4) in renal ADMA handling. However, prostanoid renal physiology and pharmacology can differ between species and validating our murine work in human tissue studies remains the subject of investigation. Nonetheless, this work reveals the downstream mechanisms that underpin the COX-2/ADMA axis (summarized in the graphical abstract) and emphasize the potential importance and added value of ADMA as a biomarker approach to assessing the cardiovascular safety of drugs that target the prostaglandin cascade.

Authors' contributions

Conceived/designed work (N.S.K., P.J.J., J.A.M.). Acquired/analysed/interpreted data (N.S.K., J.R., B.A., S.I.M., M.L.E., J.A.M.). Drafted manuscript (N.S.K., P.J.J., J.A.M.). Provided essential research tools/samples (B.L., M.L.E., M.G.C., X.W., W.W., D.C.Z., R.N., Y.Z.). Reviewed manuscript (N.S.K., J.R., B.A., B.L., S.I.M., M.L.E., M.G.C., X.W., W.W., D.C.Z., R.N., Y.Z., P.J.J., J.A.M.).

Acknowledgements

The authors thank Hime Gashaw and Fred Lih for technical assistance and Kelvin Jia Peng Chen, Yan Zhuang, Xuan Rui NG, Chenghao Liu, and Ming Keat SNG for providing *Ppard*^{-/-} mice and related expertise.

Conflict of interest: P-JJ. is a board member for Gesynta Pharma and M.G.C. is an employee of Eli Lilly and Company, both of which are developing mPGES-1 inhibitor drugs for the treatment of inflammatory disease. P-JJ. also holds patents related to mPGES-1 inhibition. J.A.M. has acted as consultant and expert witness in cases relating to anti-inflammatory medications and is on the scientific advisory board Antibe Therapeutics. All other authors have no conflict of interest.

Funding

This work was supported by a British Heart Foundation programme grant (PG/18/4/33541 to J.A.M. and N.S.K.), a British Heart Foundation Intermediate Basic Science Research Fellowship (FS/16/1/31699; to N.S.K.), an Imperial College Junior Research Fellowship (PS2129 to N.S.K.), a Royal Society Research Grant (RG150248 to N.S.K.), grants from the National Natural Science Foundation of China (81470572 to Y.Z. and 81370384 to B.L.), the Intramural Program of the NIH, National Institute of Environmental Health Sciences (Z01 ES025034 to D.C.Z.), a grant from the Singapore Ministry of Education under its Singapore Ministry of Education Academic Research Fund Tier 2 (to X.W. and W.W., MOE2014-T2-1-036) and Start-Up grants from the Lee Kong Chian School of Medicine, Nanyang Technological University (to X.W. and W.W.), Swedish Research Council (2017-02577 to P-JJ.), Innovative Medicines Initiative (EU/EFPIA) (ULTRA-

DD; 115766 to P-JJ.), Stockholm County Council (ALF; 20160378 to P-JJ.), the Swedish Rheumatism Association (R-755861 to P-JJ.); King Gustaf V's 80-year foundation (to P-JJ.); Funds from Karolinska Institutet (to P-JJ.); Cancerfonden (to P-JJ.); Radiumhemmets forskningsfonde (to P-JJ.).

References

- Mitchell JA, Kirkby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. *Br J Pharmacol* 2018;**176**:1038–1050.
- Klein T, Nusing RM, Pfeilschifter J, Ullrich V. Selective inhibition of cyclooxygenase 2. *Biochem Pharmacol* 1994;**48**:1605–1610.
- Mitchell JA, Akaraseenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. *Proc Natl Acad Sci USA* 1993;**90**:11693–11697.
- Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PD, Milne GL, Potter CM, Al-Yamani M, Adeyemi O, Warner TD, Mitchell JA. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. *Proc Natl Acad Sci USA* 2012;**109**:17597–17602.
- Mitchell JA, Lucas R, Vojnovic I, Hasan K, Pepper JR, Warner TD. Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. *FASEB J* 2006;**20**:2468–2475.
- Kirkby NS, Zaiss AK, Urquhart P, Jiao J, Austin PJ, Al-Yamani M, Lundberg MH, MacKenzie LS, Warner TD, Nicolaou A, Herschman HR, Mitchell JA. LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression. *PLoS One* 2013;**8**:e69524.
- Komhoff M, Grone HJ, Klein T, Seyberth HW, Nusing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. *Am J Physiol* 1997;**272**:F460–F468.
- Ahmetaj-Shala B, Kirkby NS, Knowles R, Al-Yamani M, Mazi S, Wang Z, Tucker AT, Mackenzie L, Armstrong PC, Nusing RM, Tomlinson JAP, Warner TD, Leiper J, Mitchell JA. Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs. *Circulation* 2015;**131**:633–642.
- Harris RC. COX-2 and the kidney. *J Cardiovasc Pharmacol* 2006;**47**(Suppl. 1):S37–S42.
- Crescente M, Armstrong PC, Chan MV, Edin ML, Lih FB, Jiao J, Gaston-Massuet C, Cottrell GS, Kirkby NS, Mitchell JA, Zeldin DC, Herschman HR, Warner TD. Platelet cox-1 knockout mouse as a model of the effects of aspirin in the cardiovascular system. *Heart* 2017;**103**:A108.3.
- Schrör K. Why we should not skip aspirin in cardiovascular prevention. *Hamostaseologie* 2016;**36**:33–43.
- Gitlin JM, Loftin CD. Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice. *Cardiovasc Res* 2008;**81**:400–407.
- Kirkby NS, Lundberg MH, Wright WR, Warner TD, Paul-Clark MJ, Mitchell JA. COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks. *PLoS One* 2014;**9**:e98165.
- Narasimha A, Watanabe J, Lin JA, Hama S, Langenbach R, Navab M, Fogelman AM, Reddy ST. A novel anti-atherogenic role for COX-2—potential mechanism for the cardiovascular side effects of COX-2 inhibitors. *Prostaglandins Other Lipid Mediat* 2007;**84**:24–33.
- Rott D, Zhu J, Burnett MS, Zhou YF, Zalles-Ganley A, Ogunmakinwa J, Epstein SE. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. *J Am Coll Cardiol* 2003;**41**:1812–1819.
- Yu Z, Crichton I, Tang SY, Hui Y, Ricciotti E, Levin MD, Lawson JA, Pure E, FitzGerald GA. Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. *Proc Natl Acad Sci USA* 2012;**109**:6727–6732.
- Barbieri SS, Amadio P, Gianelli S, Tarantino E, Zacchi E, Veglia F, Howe LR, Weksler BB, Mussoni L, Tremoli E. Cyclooxygenase-2-derived prostacyclin regulates arterial thrombus formation by suppressing tissue factor in a sirutin-1-dependent manner. *Circulation* 2012;**126**:1373–1384.
- Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, Fitzgerald GA. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. *J Clin Invest* 2006;**116**:1391–1399.
- Yu Y, Ricciotti E, Scalia R, Tang SY, Grant G, Yu Z, Landesberg G, Crichton I, Wu W, Pure E, Funk CD, FitzGerald GA. Vascular COX-2 modulates blood pressure and thrombosis in mice. *Sci Transl Med* 2012;**4**:132ra54.
- Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhalra N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawke E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanasa A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet* 2013;**382**:769–779.

21. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Juni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. *BMJ* 2011;**342**:c7086.
22. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. *PLoS Med* 2011;**8**:e1001098.
23. Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, Brophy JM. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data. *BMJ* 2017;**357**:j1909.
24. Patrignani P, Patrono C. Cyclooxygenase inhibitors: from pharmacology to clinical read-outs. *Biochim Biophys Acta* 2015;**1851**:422–432.
25. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. *Pharmacol Rev* 2007;**59**:207–224.
26. Friesen RW, Mancini JA. Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target. *J Med Chem* 2008;**51**:4059–4067.
27. Howe LR, Subbaramaiah K, Kent CV, Zhou XK, Chang SH, Hla T, Jakobsson PJ, Hudis CA, Dannenberg AJ. Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis. *Prostaglandins Other Lipid Mediat* 2013;**106**:99–105.
28. Korotkova M, Jakobsson PJ. Characterization of microsomal prostaglandin E synthase 1 inhibitors. *Basic Clin Pharmacol Toxicol* 2014;**114**:64–69.
29. Norman BH, Fisher MJ, Schiffler MA, Kuklish SL, Hughes NE, Czeskis BA, Cassidy KC, Abraham TL, Alberts JJ, Luffer-Atlas D. Identification and mitigation of reactive metabolites of 2-aminoimidazole-containing microsomal prostaglandin E synthase-1 inhibitors terminated due to clinical drug-induced liver injury. *J Med Chem* 2018;**61**:2041–2051.
30. Caplin B, Leiper J. Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators? *Arterioscler Thromb Vasc Biol* 2012;**32**:1343–1353.
31. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, Pandher K, Lapointe JM, Saha S, Roach ML, Carter D, Thomas NA, Durtschi BA, McNeish JD, Hambor JE, Jakobsson PJ, Carty TJ, Perez JR, Audoly LP. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. *Proc Natl Acad Sci USA* 2003;**100**:9044–9049.
32. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A, Oh-Ishi S, Narumiya S. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. *Nature* 1997;**388**:678–682.
33. Nadra K, Anghel SI, Joye E, Tan NS, Basu-Modak S, Trono D, Wahli W, Desvergne B. Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. *Mol Cell Biol* 2006;**26**:3266–3281.
34. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Ushikubi F, Narumiya S, Sugimura T, Wakabayashi K. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. *Cancer Res* 1999;**59**:5093–5096.
35. Hizaki H, Segi E, Sugimoto Y, Hirose M, Saji T, Ushikubi F, Matsuoka T, Noda Y, Tanaka T, Yoshida N, Narumiya S, Ichikawa A. Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2). *Proc Natl Acad Sci USA* 1999;**96**:10501–10506.
36. Ushikubi F, Segi E, Sugimoto Y, Murata T, Matsuoka T, Kobayashi T, Hizaki H, Tuboi K, Katsuyama M, Ichikawa A, Tanaka T, Yoshida N, Narumiya S. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. *Nature* 1998;**395**:281–284.
37. Segi E, Sugimoto Y, Yamasaki A, Aze Y, Oida H, Nishimura T, Murata T, Matsuoka T, Ushikubi F, Hirose M, Tanaka T, Yoshida N, Narumiya S, Ichikawa A. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. *Biochem Biophys Res Commun* 1998;**246**:7–12.
38. Matsuoka T, Hirata M, Tanaka H, Takahashi Y, Murata T, Kabashima K, Sugimoto Y, Kobayashi T, Ushikubi F, Aze Y, Eguchi N, Urade Y, Yoshida N, Kimura K, Mizoguchi A, Honda Y, Nagai H, Narumiya S. Prostaglandin D2 as a mediator of allergic asthma. *Science* 2000;**287**:2013–2017.
39. Xu H, Yang J, Gao W, Li L, Li P, Zhang L, Gong YN, Peng X, Xi JJ, Chen S, Wang F, Shao F. Innate immune sensing of bacterial modifications of Rho GTPases by the P2Y12 inflammasome. *Nature* 2014;**513**:237–241.
40. Newman JW, Watanabe T, Hammock BD. The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. *J Lipid Res* 2002;**43**:1563–1578.
41. Mitchell JA, Knowles RB, Kirkby NS, Reed DM, Edin ML, White WE, Chan MV, Longhurst H, Yaqoob MM, Milne GL, Zeldin DC, Warner TD. Kidney transplantation in a patient lacking cytosolic phospholipase A2 proves renal origins of urinary PGI-M and TX-M. *Circ Res* 2018;**122**:555–559.
42. Zhou Y, Luo W, Zhang Y, Li H, Huang D, Liu B. Cyclo-oxygenase-1 or -2-mediated metabolism of arachidonic acid in endothelium-dependent contraction of mouse arteries. *Exp Physiol* 2013;**98**:1225–1234.
43. Mitchell JA, Knowles RB, Kirkby NS, Reed DM, Edin ML, White WE, Chan MV, Longhurst H, Yaqoob MM, Milne GL, Zeldin DC, Warner TD. Letter by Mitchell et al Regarding Article, “Urinary Prostaglandin Metabolites: an Incomplete Reckoning and a Flush to Judgment”. *Circ Res* 2018;**122**:e84–e85.
44. Liu B, Luo W, Zhang Y, Li H, Zhang J, Tan XR, Zhou Y. Concomitant activation of functionally opposing prostacyclin and thromboxane prostanoid receptors by cyclo-oxygenase-1-mediated prostacyclin synthesis in mouse arteries. *Exp Physiol* 2012;**97**:895–904.
45. Sourij H, Meinitzer A, Pilz S, Grammer TB, Winkelmann BR, Boehm BO, Marz W. Arginine bioavailability ratios are associated with cardiovascular mortality in patients referred to coronary angiography. *Atherosclerosis* 2011;**218**:220–225.
46. Ricciotti E, Castro C, Tang SY, Briggs WTE, West JA, Malik D, Rhoades SD, Meng H, Li X, Lahens NF, Sparks JA, Karlson EV, Weljie AM, Griffin JL, FitzGerald GA. Cyclooxygenase-2, asymmetric dimethylarginine and the cardiovascular hazard from NSAIDs. *Circulation* 2018;**138**:2367.
47. Salazar F, Vazquez ML, Masferrer JL, Mbalavie G, Llinas MT, Saez F, Arhancet G, Salazar FJ. Renal effects induced by prolonged mPGES1 inhibition. *Am J Physiol Renal Physiol* 2014;**306**:F68–F74.
48. Jin Y, Smith CL, Hu L, Campanale KM, Stoltz R, Huffman LG Jr, McNearney TA, Yang XY, Ackermann BL, Dean R, Regev A, Landschulz W. Pharmacodynamic comparison of LY3023703, a novel microsomal prostaglandin e synthase 1 inhibitor, with celecoxib. *Clin Pharmacol Ther* 2016;**99**:274–284.
49. Jia Z, Zhang Y, Ding G, Heiney KM, Huang S, Zhang A. Role of COX-2/mPGES-1/prostaglandin E2 cascade in kidney injury. *Mediators Inflamm* 2015;**2015**:147894.
50. Ali FY, Egan K, FitzGerald GA, Desvergne B, Wahli W, Bishop-Bailey D, Warner TD, Mitchell JA. Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. *Am J Respir Cell Mol Biol* 2006;**34**:242–246.
51. Francois H, Facemire C, Kumar A, Audoly L, Koller B, Coffman T. Role of microsomal prostaglandin E synthase 1 in the kidney. *J Am Soc Nephrol* 2007;**18**:1466–1475.

Translational perspective

Non-steroidal anti-inflammatory drugs (NSAIDs) treat pain and inflammation and can prevent cancer but cause serious cardiovascular side effects resulting in the virtual arrest in development of drugs which target prostanoid pathways. This includes new cyclooxygenase (COX)-2 blockers and inhibitors of microsomal prostaglandin E synthase-1 (mPGES-1). Our work has indicated that the well-established cardiotoxic biomarker, asymmetric dimethylarginine (ADMA), is increased when COX-2 is lost. In this study, we reveal the downstream signalling pathways responsible for the protective break that COX-2 exerts on ADMA and that this is independent of the mPGES-1 pathway. Together these studies, support the idea that ADMA has utility as a biomarker and that in this setting mPGES-1 inhibitors spare the pathways associated with NSAID cardiovascular toxicity.